Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

EuroEyes International Eye Clinic Limited
德視佳國際眼科有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 1846)

VOLUNTARY ANNOUNCEMENT THE TOTAL NUMBER OF EYE SURGERIES FOR THE THIRD QUARTER OF 2026

EuroEyes International Eye Clinic Limited (the "**Company**"), together with its subsidiaries (the "**Group**"), on a voluntary basis, makes this announcement. The board (the "**Board**") of directors (the "**Directors**" and each a "**Director**") of the Company wishes to announce, according to the Company's preliminary statistics and the information currently available to the Company, the combined total number of eye surgeries performed by the Group (collectively the "**Eye Surgeries**") from 1 July 2026 to 30 September 2026 (the "**Third Quarter of 2026**").

The total number of Eye Surgeries for the Third Quarter of 2026 was 10,301, representing an increase of approximately 51.3% when compared to the same period of 2025 (from 1 July 2025 to 30 September 2025: 6,807). The rise was primarily attributable to the inclusion of FYEO Europe B.V. ("**FYEO**") following the completion of its acquisition on 22 July 2026, alongside operations in Switzerland. FYEO showed a robust performance in the Third Quarter of 2026, with the number of eye surgeries increasing by 2.1% compared to the same period in 2025, driven by growth in phakic lens surgery (ICL) and lens exchange procedures. Excluding FYEO and Switzerland operations, the organic number of eye surgeries was 6,211, with the decline mainly concentrated in Germany and Denmark. Operations in both Germany and Denmark faced some challenges, prompting the Group to implement targeted remedial measures. An operational recovery in Germany is currently anticipated by the first quarter of 2027, while improvements in Denmark are expected to materialise by the end of 2026.

The figures set out in this announcement have not been audited and may differ from the final actual figures. Investors are reminded to exercise caution when dealing in the shares of the Company.

This announcement is made by the order of the Board, of which the Directors individually and jointly accepts responsibility for the accuracy of this announcement.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
EuroEyes International Eye Clinic Limited
Dr. Jørn Slot Jørgensen
Chairman and Executive Director

Hong Kong, 18 November 2026

As at the date of this announcement, the Board comprises Dr. Jørn Slot Jørgensen, Mr. Jannik Jonas Slot Jørgensen, Professor Dan Zoltan Reinstein and Mr. Markus Schröder as executive Directors; Mr. Marcus Huascar Bracklo as a non-executive Director; and Mr. Hans Helmuth Hennig, Ms. Katherine Rong Xin and Mr. Philip Duncan Wright as independent non-executive Directors.